Pacira Bio Sciences, Inc. PCRX
We take great care to ensure that the data presented and summarized in this overview for Pacira BioSciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PCRX
View all-
Black Rock Inc. New York, NY8.01MShares$190 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.2MShares$124 Million0.0% of portfolio
-
Doma Perpetual Capital Management LLC Miami, FL2.7MShares$64.2 Million23.38% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$51.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.14MShares$50.8 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.94MShares$46.2 Million0.03% of portfolio
-
State Street Corp Boston, MA1.9MShares$45.2 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.89MShares$44.8 Million0.07% of portfolio
-
American Century Companies Inc Kansas City, MO1.38MShares$32.8 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY1.31MShares$31.2 Million0.0% of portfolio
Latest Institutional Activity in PCRX
Top Purchases
Top Sells
About PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Insider Transactions at PCRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Shawn Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,104
-13.93%
|
$227,600
$25.14 P/Share
|
|
Dec 10
2025
|
Shawn Cross Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,104
+12.23%
|
$145,664
$16.45 P/Share
|
|
Dec 09
2025
|
Shawn Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,896
-22.03%
|
$397,400
$25.03 P/Share
|
|
Dec 09
2025
|
Shawn Cross Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,896
+18.06%
|
$254,336
$16.45 P/Share
|
|
Nov 17
2025
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,960
-2.17%
|
$95,040
$24.09 P/Share
|
|
Nov 10
2025
|
Shawn Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,060
-17.65%
|
$265,320
$22.09 P/Share
|
|
Oct 31
2025
|
Shawn Cross Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,690
-8.92%
|
$140,490
$21.38 P/Share
|
|
Sep 04
2025
|
Abraham Ceesay Director |
SELL
Open market or private sale
|
Direct |
2,354
-20.66%
|
$63,558
$27.19 P/Share
|
|
Aug 07
2025
|
Marcelo Bigal Director |
SELL
Open market or private sale
|
Direct |
4,912
-30.13%
|
$112,976
$23.67 P/Share
|
|
Aug 01
2025
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
315
-0.17%
|
$6,930
$22.07 P/Share
|
|
Jun 11
2025
|
Laura Brege Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+20.63%
|
-
|
|
Jun 11
2025
|
Alethia Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+35.1%
|
-
|
|
Jun 11
2025
|
Christopher Christie Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+27.01%
|
-
|
|
Jun 11
2025
|
Michael J. Yang Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+31.51%
|
-
|
|
Jun 11
2025
|
Marcelo Bigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+27.43%
|
-
|
|
Jun 11
2025
|
Mark Froimson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+23.0%
|
-
|
|
Jun 11
2025
|
Abraham Ceesay Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+35.1%
|
-
|
|
Jun 11
2025
|
Mark A. Kronenfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,999
+22.27%
|
-
|
|
Jun 04
2025
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
5,578
-8.56%
|
$145,028
$26.21 P/Share
|
|
Jun 04
2025
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
14,376
-8.17%
|
$373,776
$26.24 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 661K shares |
|---|---|
| Exercise of conversion of derivative security | 25K shares |
| Payment of exercise price or tax liability | 31.5K shares |
|---|---|
| Open market or private sale | 69.1K shares |